SubHero Banner

Lynparza® (olaparib) – New formulation approval

August 17, 2017 – AstraZeneca announced the FDA approval of Lynparza (olaparib) tablets, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.

Download PDF